Jim Cramer
We’re lightening up on a rallying stock that’s grown too big in our portfolio
The sale also comes as our trusted momentum indicator moved further into overbought territory. Source
Read More
We’re trimming a 2025 top gainer, taking profits on the market’s rotation into health stocks
We are selling 75 shares of GE Healthcare at roughly $90 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 900 shares of GEHC, decreasing its weighting to about 2.25% from 2.42%. We’re taking advantage of the market’s rotation into health-care stocks by locking in profits in GE Healthcare. Following an up-and-down 2024, GE […]
Read More
Our 5 top-performing portfolio stocks since December’s Monthly Meeting are tech free
It’s been a topsy-turvy start to 2025 for the stock market. Since the Club’s December Monthly Meeting, Wall Street has been barraged by headlines that sent equities seesawing down and then up. The S & P 500 wrapped up 2024 with a roughly 23% gain despite tumbling in the final four sessions of the year and […]
Read More
Stocks pop on cool inflation, hot bank earnings — plus, new rules on biotech exports to China
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Wall Street surged Wednesday thanks to the second encouraging inflation report this week and a batch of strong bank earnings. The consumer price index, excluding […]
Read More
9 questions we want answered when our 3 financial names report earnings Wednesday
Wall Street’s biggest financial institutions kick off fourth-quarter earnings on Wednesday, with portfolio names Wells Fargo , Goldman Sachs , and BlackRock set to report results before the opening bell. The rally in financial stocks last year, which really started in October 2023, went into high gear in the run-up to the Federal Reserve ushering […]
Read More
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]
Read More
How five top CEOs described the AI boom in 2024
Throughout 2024, CNBC’s Jim Cramer discussed the seemingly boundless rise of artificial intelligence with dozens of CEOs across the tech world. Here is how five top enterprise leaders characterized AI’s meteoric rise this year. Nvidia CEO Jensen Huang said the “AI computing ramp” is only beginning and will last years. Huang in March painted a […]
Read More
Bargain hunting: These 8 portfolio stocks look quite cheap, but only some are worth buying
The holiday shopping season has come and gone. When it comes to stock picking, at least, the desire to find a bargain is as strong as ever. A recent analysis of our portfolio revealed we own more than a couple cheap stocks, including one of our newer additions in Bristol Myers Squibb . Still, we’re […]
Read More
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]
Read More
Eli Lilly looks to extend its winning streak over the broader market to 6 years
Eli Lilly has outperformed the S & P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question. Year-to-date performance: Up 33.7% Forward price-to-earnings ratio: 34.3 versus five-year average of 34.5 Our rating: Buy-equivalent 1 Our price target: […]
Read More